Adding a Personal Touch to the Management of Individuals Living with Blood Cancer

| January 16, 2017

article image
The past half century has witnessed an impressive understanding of cancer in general, and the cancer genome in particular, not just in hematological malignancies, but in diverse cancers. We also firmly recognize the relationship between the cancer cell and its normal tissue microenvironment, and the interplay between this microenvironment and the immune system and the broader concept of inflammation. We now know that about 20 percent of human cancers are related to chronic inflammationi caused by diverse factors, such as autoimmune disease, irritants and infections, such as Helicobacter pylori infections in a subtype of gastric lymphoma. As our understanding of the underlying molecular biology, the cancer ecosystem and cancer-related inflammation improves, we are beginning to appreciate the complexity of the diverse processes and their profound effects on the tissue microenvironment and the malignant clone.

Spotlight

Avanti Polar Lipids, Inc.

Discover The Difference.....that comes with having over 40 years of experience manufacturing lipids - the unique reputation for purity,a dedicated Customer Service group and an informed Technical Support team. At Avanti Polar Lipids, Inc., our mission is to provide research and pharmaceutical scientists with the highest quality phospholipids, sphingolipids and sterols. To accomplish our mission, Avanti uses only the finest precursors and reagents and our highly trained staff utilize proven methods and procedures to ensure the quality of the final product. Each product is certified by our analytical specialists according to a rigorous set of specifications.

OTHER ARTICLES

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Spotlight

Avanti Polar Lipids, Inc.

Discover The Difference.....that comes with having over 40 years of experience manufacturing lipids - the unique reputation for purity,a dedicated Customer Service group and an informed Technical Support team. At Avanti Polar Lipids, Inc., our mission is to provide research and pharmaceutical scientists with the highest quality phospholipids, sphingolipids and sterols. To accomplish our mission, Avanti uses only the finest precursors and reagents and our highly trained staff utilize proven methods and procedures to ensure the quality of the final product. Each product is certified by our analytical specialists according to a rigorous set of specifications.

Events